EOG Resources Inc vs Cassava Sciences Inc — how do they compare? EOG Resources Inc trades at $149.35 (market cap $77.90B), while Cassava Sciences Inc trades at $0.83 (market cap $39.40M). The key difference: EOG Resources Inc is far larger — about 1977.2× Cassava Sciences Inc's market cap, and EOG Resources Inc pays a 2.75% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Cassava Sciences Inc for 37 Days on average.
| EOG | FLNA | |
|---|---|---|
Market Cap | $77.90B | $39.40M |
Volume | 2,930,386 | 759,018 |
Sector | Energy | Health |
52-Week High | $153.74 | $4.64 |
52-Week Low | $101.78 | $0.68 |
Typical Hold Time | 59 Days | 37 Days |
Enterprise Value | $81.24B | -$43.28M |
Dividend Yield | 2.75% | — |
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $149.40, up 3.6% today, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.07 exceeding expectations. Valuation ratios appear attractive, including a P/E of 11.56 and EV/EBITDA of 5.84. Recent news highlights robust operational execution and disciplined capital allocation, with the company announcing a CFO transition and scheduling its Q3 2026 earnings call for November 6.
The outlook for EOG remains positive, supported by strong profitability metrics, a solid balance sheet, and a unanimous analyst buy/hold consensus with no sell ratings. Key opportunities include projected revenue growth to $26.6B in 2026 and a 5% oil volume growth target. Risks involve exposure to volatile oil prices, as seen in recent price retreats impacting energy stocks, and potential execution challenges amid macroeconomic uncertainty. The stock offers value with a consensus price target of $164.77, implying ~10% upside.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →